AHCL vs NOVARTIND: Stock Comparison

Anlon Healthcare Limited vs Novartis India Limited

Live data: 24 July 2026, 4:08 PM IST • Source: NSE and company filings

Novartis India Limited is the larger company by market capitalisation. Anlon Healthcare Limited shows a lower P/E, a higher ROE and a higher ROCE, while Novartis India Limited shows a higher dividend yield, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Anlon Healthcare Limited and Novartis India Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AHCL is more favourable on 5 of 13 scored metrics and NOVARTIND on 8These counts are context-free and are not an overall rating.

Key Differences

Market Cap
NOVARTIND is the larger company
₹4,062 Cr vs ₹797 Cr
P/E Ratio
AHCL has a lower P/E
27.78x vs 41.85x
P/B Ratio
AHCL has a lower P/B
3.46x vs 5x
EPS
NOVARTIND has higher earnings per share
₹37.76 vs ₹0.61
Dividend Yield
NOVARTIND has a higher dividend yield
1.7% vs 0%
Revenue Growth (TTM YoY)
NOVARTIND has faster revenue growth
8% vs 4%
EPS Growth (TTM YoY)
NOVARTIND has faster EPS growth
-13.8% vs -54.8%
Qtr Sales Growth
NOVARTIND has stronger quarterly sales growth
7.95% vs 4.01%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAHCLNOVARTIND
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAHCLNOVARTIND
Live Price₹15.01₹1,641.2
Day Change-0.46%-1.9%
Volume28.27 L54,369
52-Week High₹161₹1,780
52-Week Low₹12.91₹950
Distance from 52W High-90.68%-7.8%

Valuation

MetricAHCLNOVARTIND
Market Cap₹797 Cr₹4,062 Cr
P/E Ratio27.78x41.85x
P/B Ratio3.46x5x
EPS₹0.61₹37.76
Book Value₹5.11₹331.34
Dividend Yield0%1.7%

Growth

MetricAHCLNOVARTIND
Revenue Growth (TTM YoY)4%8%
EPS Growth (TTM YoY)-54.8%-13.8%
Qtr Sales Growth4.01%7.95%
Qtr Profit Growth-36.9%-13.8%

Profitability & Leverage

MetricAHCLNOVARTIND
ROE18.4%11.6%
ROCE20.8%16.2%
Net Margin22.18%26.3%
Operating Margin27.6%26.6%
Debt to Equity0.19x0x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricAHCLNOVARTIND
Promoter Holding52.68%0%
FII Holding0.32% 0.09 pp0.17% 0.02 pp
DII Holding4.6% 0.11 pp0.53% 0.11 pp
Public Holding42.4% 0.2 pp28.61% 0.11 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Anlon Healthcare Limited and Novartis India Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.